Kai Hsiung Chang 張凱雄 助研究員

The translational research in my laboratory is to discover molecular changes that cause treatment resistance in prostate cancer. We use the transcriptome and in-silico metabolic simulation to investigate the re-wired metabolisms during drug treatment. From the treatment-altered metabolic pathways, the actionable drug targets and disease biomarkers are identified and further validated in pre-clinical models. Over the past few years, we have characterized major metabolic reprogramming in the 2nd generation hormone therapy resistance tumors and delineated a new mechanism for the trans-differentiation of the adenocarcinoma tumor into a neuroendocrine prostate cancer (NEPC). The validation these discoveries in patients is ongoing, which holds great promise for improvement of men’s health and life quality, especially in ageing countries. Also, we try to regulate lineage switch by harnessing our discoveries of metabolic reprogramming in trans-differentiation, contributing to fulfillment of the unmet needs in regenerative medicine.


2004 – 2008 Ph.D., Pharmacology, Rutgers University/University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
2001 – 2004 M.S., Molecular and Cellular Biology, National Taiwan University, Taipei, Taiwan
1995 – 1999 B.S., Biology, National Taiwan Normal University, Taipei, Taiwan


2016/02 – present Assistant Investigator, Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan, Taiwan
2013 – 2015 Research Associate, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
2009 – 2013 Postdoctoral Researcher, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA


姓名 職稱 分機 E-mail
溫慧勤 研究助理 37515 huichin@nhri.edu.tw
陳玉蓮 研究助理 37515 cyl@nhri.edu.tw



PubMed Search

NHRI Institutional Repository國家衛生研究院機構典藏

Share Button

Comments are closed.